

ImCheck Therapeutics appoints Dr. Debasish Roychowdhury
as its independent Chairman of the Board

With over a decade of patient care as a hematologist/oncologist and a career as a big pharma senior executive in R&D, regulatory and commercial operations, Dr. Roychowdhury is a recognized leader in the pharmaceutical industry & oncology product development.

Marseille, France, 25 May 2018 – ImCheck Therapeutics, an emerging biopharmaceutical company developing a new generation of immunomodulatory antibodies against cancer and auto-immune diseases, announces the appointment of Dr. Debasish Roychowdhury as its independent Chairman of the Board.

Dr. Roychowdhury is a hematologist/oncologist with over a decade of patient care, academic research and teaching experience as well as over 15 years of pharmaceutical industry and senior management experience.

Dr. Roychowdhury is a leader in the pharmaceutical industry across multiple functional and cross-functional areas, regions and matrices, including – all stages of R&D, regulatory, commercial operations and medical affairs, market access, business development and alliance management.

During his career in the top 10 pharmaceutical companies, Dr. Roychowdhury was the Senior Vice President and Head of the Global Oncology Division at Sanofi. Prior to that, he served as the Vice President for Clinical Development at GlaxoSmithKline and directed the Oncology global regulatory group at Eli Lilly and Company.

Among many other achievements, Debasish career includes 9 drug approvals in the U.S. and in Europe, the establishment of Sanofi's Oncology Division (notably Genzyme's integration), founding Partner Therapeutics and successfully supporting biotech companies (notably Seragon Pharmaceuticals sale to Roche/Genentech).

Debasish currently consults many pharma & biotech companies and serves as a member of the Board of Directors for Partner Therapeutics, Lytix Biopharma AS, Celyad S.A., and Fund+, a life sciences investment fund.

« We are delighted to benefit from the huge experience and network of Debasish to drive our Board at a point where we are preparing to bring two of our programs in the clinic by 2020. I would like to warmly thank Rémi Droller for his contribution & guidance while he served as our Chairman since the company's inception. Rémi, along with the rest of our investor's representatives, has been tremendously supportive and helpful over the critical period of establishing the company and concluding our Series A, » **said Pierre d'Epenoux, CEO of ImCheck Therapeutics.**

"I am pleased to join and lead ImCheck's Board of Directors and contribute to the company's future development. ImCheck with its innovative research and novel pipeline driven by world class scientists and supportive investors, is one of the most exciting emerging companies in the field of immunotherapy," **added Dr. Debasish Roychowdhury**

" I look forward to supporting Pierre and his team to bring this science to patients."

About IMCHECK THERAPEUTICS

A spin-off of the C.R.C.M., Marseille's Cancer Research Center (IPC, Inserm, CNRS, AMU), ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators with a highly-differentiated & diversified portfolio of first-in-class therapeutic antibodies in cancers and auto-immunity.

Co-founded in 2015 by Daniel Olive, a worldwide recognized leader in innate immunity & co-signaling molecules, Professor of Immunology at Aix-Marseille University & Institut Paoli-Calmettes and Head of the immune monitoring program for early-stage oncology clinical trials at IPC.

With a precision medicine-based translational approach and several established academic collaborations with renowned institutions, ImCheck is uniquely positioned to develop theragnostic candidates for precision & personalized medicine in cancers and auto-immunity diseases.

To date, ImCheck is developing two first-in-class immunomodulator antibodies and is advancing several discovery programs on undisclosed targets, all playing a defined immune-modulating role in both innate and adaptive immunity.

The company is based in Marseille and is engaged in an active recruitment dynamic.

For more information, please visit www.imchecktherapeutics.com

Press contact: ATCG Partners

Marie Puvieux

Mob: +33 (0)6 10 54 36 72

imcheck@atcg-partners.com